Sunshine Biopharma, Inc. (SBFM)
| Market Cap | 891.79K -89.1% |
| Revenue (ttm) | 35.35M -2.7% |
| Net Income | -5.83M |
| EPS | -8.20 |
| Shares Out | 3.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,574,811 |
| Open | 0.2294 |
| Previous Close | 0.2430 |
| Day's Range | 0.1855 - 0.2300 |
| 52-Week Range | 0.1855 - 24.3000 |
| Beta | 1.35 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About SBFM
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurin... [Read more]
Financial Performance
In 2025, Sunshine Biopharma's revenue was $36.31 million, an increase of 4.11% compared to the previous year's $34.87 million. Losses were -$5.98 million, 16.4% more than in 2024.
Financial StatementsNews
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
$6.0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrants FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / Sunshine Biopharma I...
Sunshine Biopharma prices $6.0M public offering
Sunshine Biopharma (SBFM) announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before…
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
FORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications...
Sunshine Biopharma files to sell 10.18M common units
Aegis Capital is acting as exclusive placement agent in connection with this offering.
Sunshine Biopharma launches generic Zofran in Canada
Sunshine Biopharma (SBFM) has launched generic Ondansetron tablets of 4mg and 8mg in the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran. Ondansetron is widely prescri...
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery Global ondansetron market projected to reach $2.98 billion by 20...
Sunshine Biopharma advances lead Coronavirus drug candidate
Sunshine Biopharma (SBFM) announces that it has advanced its lead Coronavirus drug candidate into IND-enabling studies. The Company had previously published laboratory results on its library of Anti-C...
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activity Significant dose-dependent suppression of pulmonary viral replication in vivo Strong oral bioavailability and preferent...
Sunshine Biopharma announces Health Canada approval for atenolol
Sunshine Biopharma (SBFM) announced the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin. Atenolol…
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription med...
Sunshine Biopharma files to sell 24.48M shares of common stock
16:19 EDT Sunshine Biopharma (SBFM) files to sell 24.48M shares of common stock
Sunshine Biopharma provides update, outlines plans for oncology project
Sunshine Biopharma (SBFM) provided an update and outlined next plans for its oncology project, the K1.1 mRNA lipid nanoparticle program. The gene encoding the K1.1 mRNA is a tumor suppressor…
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
K1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma models Program targets a tumor suppressor frequently mutated in difficult-to-treat lung...
Sunshine Biopharma receives Canadian regulatory approval for Enalapril
Sunshine Biopharma (SBFM) announces the approval of its generic Enalapril tablets 2.5mg, 5mg, 10mg and 20mg for the Canadian market. Enalapril is the generic equivalent of the brand name, Vasotec.
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
Global anti-hypertensive drug market projected to reach $37.24 billion by 2034 Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction...
Sunshine Biopharma launches generic amoxicillin formulation in Canada
Sunshine Biopharma (SBFM) announced the launch of its generic Amoxicillin formulation in the Canadian market. Sunshine Biopharma’s generic version will be available in multiple dosages and strengths, ...
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengths Launch expands Sunshine Biopharma's growing portfolio of essential prescription medications Globa...
Sunshine announces approval of generic Dienogest tablets for Canadian market
Sunshine Biopharma (SBFM) announce the approval of its generic Dienogest tablets of 2mg for the Canadian market. Dienogest is the generic equivalent of the brand name, Visanne Dienogest works through…
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
Dienogest is first-line therapy for pelvic pain associate with endometriosis The endometriosis treatment market is projected to reach $5.2 billion by 2034 FORT LAUDERDALE, FL / ACCESS Newswire / Augus...
Sunshine Biopharma announces approval of generic Ondansetron tablets
Sunshine Biopharma (SBFM) announces the approval of its generic Ondansetron tablets of 4mg and 8mg for the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran. Sunshine…
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
FORT LAUDERDALE, FL / ACCESS Newswire / July 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medic...
Sunshine Biopharma announces publication of new results on MR1-114
Sunshine Biopharma (SBFM) announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor, MR1-114, with nanomolar poten...
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
FORT LAUDERDALE, FL / ACCESS Newswire / July 20, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medic...
Sunshine Biopharma receives Canadian approval for generic Arimidex
Sunshine Biopharma (SBFM) announced the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the brand name breast cancer drug, Arimidex...
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
FORT LAUDERDALE, FL / ACCESS Newswire / June 25, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medic...